Regeneron Pharmaceuticals, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-03-10$744.83 RISE2025-06-05$483.07 PEAK2025-08-21$598.16 164d | -35.1% 87d | 2025-03-31 $634.23 | 2025-08-21 $598.16 | 84Quality on Sale | 88Quality on Sale | +23.8% 77d | -5.7% Held 143d |
DROP2023-04-13$830.35 RISE2023-07-07$692.45 PEAK2023-08-21$844.37 130d | -16.6% 85d | Missed | Missed | — | — | +21.9% 45d | Missed |
DROP2022-05-27$692.80 RISE2022-09-06$573.97 PEAK2022-11-01$759.91 158d | -17.2% 102d | Missed | Missed | — | — | +32.4% 56d | Missed |
DROP2022-04-08$738.84 RISE2022-08-02$574.96 PEAK2022-10-13$752.56 188d | -22.2% 116d | Missed | Missed | — | — | +30.9% 72d | Missed |
DROP2022-04-08$738.84 RISE2022-06-14$548.35 PEAK2022-09-09$724.32 154d | -25.8% 67d | Missed | Missed | — | — | +32.1% 87d | Missed |
DROP2022-04-08$738.84 RISE2022-05-09$599.77 PEAK2022-05-27$692.80 49d | -18.8% 31d | Missed | Missed | — | — | +15.5% 18d | Missed |
DROP2021-09-01$680.96 RISE2021-10-18$543.48 PEAK2021-12-14$670.97 104d | -20.2% 47d | Missed | Missed | — | — | +23.5% 57d | Missed |
DROP2020-11-05$588.81 RISE2021-03-03$446.73 PEAK2021-05-17$523.73 193d | -24.1% 118d | Missed | Missed | — | — | +17.2% 75d | Missed |
DROP2020-08-31$619.93 RISE2021-01-06$470.09 PEAK2021-01-25$548.20 147d | -24.2% 128d | Missed | Missed | — | — | +16.6% 19d | Missed |
Regeneron Pharmaceuticals (NasdaqGS:REGN) has entered a research collaboration with Parabilis Medicines to develop therapeutics for previously "undruggable" proteins. The alliance uses Parabilis' Helicon peptide platform for up to five initial targets, with scope for milestone payments and potential expansion to more programs. The partnership focuses on challenging intracellular proteins and aims to broaden Regeneron's discovery capabilities beyond its existing technology platforms. For...
If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading the way, the biotech space is more than worth exploring, especially as some of the AI benefits start to trickle downstream towards biotech ... These 2 Cheap Biotech Stocks Offer Potential for Low-Beta Growth
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical stocks to invest in according to billionaires. Canaccord cut the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 on May 19, maintaining a Buy rating on the shares. The firm updated its model on the stock after its Phase 3 study of fianlimab+cemiplimab vs […]
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the best medical stocks to invest in according to billionaires. Canaccord cut the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $875 from $1,057 on May 19, maintaining a Buy rating on the shares. The firm updated its model on the stock after its Phase 3 study of fianlimab+cemiplimab vs […]
Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.
Regeneron Pharmaceuticals has underperformed the broader market over the past year, and analysts remain reasonably bullish about the stock’s long term prospects.
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss the latest developments on the Ebola outbreak, risks to the United States, GLP-1's impact on cancer risks, and more.
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Regeneron Pharmaceuticals entered into a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis’ Helicon peptide platform. The partnership will focus on creating Helicons (stabilized, cell-penetrant alpha-helical peptides) that can be used as […]
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the cheap NASDAQ stocks to buy right now. On May 19, Regeneron Pharmaceuticals entered into a $2.32 billion research collaboration with Parabilis Medicines to develop therapeutic candidates using Parabilis’ Helicon peptide platform. The partnership will focus on creating Helicons (stabilized, cell-penetrant alpha-helical peptides) that can be used as […]
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares
Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX shares
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive early-stage trial results for Lynozyfic in systemic AL amyloidosis, with high response rates and signs of organ function improvement. The European Medicines Agency accepted Otarmeni, a gene therapy candidate for OTOF-related hearing loss, for accelerated review as a potential first treatment of its kind in Europe. These twin updates arrive at a time when NasdaqGS:REGN is trading at $638.88, with the stock down 8.5% over the past...
Regeneron Pharmaceuticals (NasdaqGS:REGN) reported positive early-stage trial results for Lynozyfic in systemic AL amyloidosis, with high response rates and signs of organ function improvement. The European Medicines Agency accepted Otarmeni, a gene therapy candidate for OTOF-related hearing loss, for accelerated review as a potential first treatment of its kind in Europe. These twin updates arrive at a time when NasdaqGS:REGN is trading at $638.88, with the stock down 8.5% over the past...
Check out the companies making headlines this week:
Check out the companies making headlines this week:
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| REGN | -12.35% | -22.26% | -20.35% | +25.39% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -15.32% | -16.54% | -16.91% | +12.71% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 4.66M | $3.60B | 0.12% | Unchanged | 2026-03-31 |
| Wellington | fundamental | 1.84M | $1.42B | 0.27% | Added+176.5% | 2026-03-31 |
| FidelityFMR | fundamental | 1.52M | $1.17B | 0.06% | Trimmed-34.5% | 2026-03-31 |
| TwoSigma | quant | 812.2K | $627.57M | 0.51% | Added+188.9% | 2026-03-31 |
| CapResearch | fundamental | 101.9K | $78.72M | 0.01% | Trimmed-1.4% | 2026-03-31 |
| RenTech | quant | 66.8K | $51.61M | 0.08% | Added+635.5% | 2026-03-31 |
| DEShaw | quant | 22.7K | $17.56M | 0.01% | Trimmed-85.4% | 2026-03-31 |
| Bridgewater | macro | 22.7K | $17.56M | 0.08% | Trimmed-68.8% | 2026-03-31 |
| TRowePrice | fundamental | 2.18M | $1.68M | 0.19% | Added+11.7% | 2026-03-31 |
| Citadel | multi-strat | 2.2K | $1.68M | 0.00% | Trimmed-99.2% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-02-23 | Zoghbi Huda Y | Director | M Option exercise(deriv) | 1,638 | — | +$0 |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 4 | $790.00 | −$3.2K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 56 | $785.61 | −$44.0K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 160 | $784.45 | −$125.5K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 220 | $783.29 | −$172.3K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 298 | $782.10 | −$233.1K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 209 | $781.28 | −$163.3K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 331 | $780.45 | −$258.3K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 208 | $779.55 | −$162.1K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 53 | $778.47 | −$41.3K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 50 | $775.50 | −$38.8K |
| 2026-02-23 | Zoghbi Huda Y | Director | S Open-market sale | 49 | $774.68 | −$38.0K |
| 2026-02-23 | Zoghbi Huda Y | Director | M Option exercise | 1,638 | $376.69 | +$617.0K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | M Option exercise(deriv) | 1,000 | — | +$0 |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 53 | $785.72 | −$41.6K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 1 | $784.66 | −$785 |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 144 | $783.23 | −$112.8K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 37 | $782.67 | −$29.0K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 26 | $781.37 | −$20.3K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 75 | $780.06 | −$58.5K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 205 | $779.56 | −$159.8K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 563 | $778.35 | −$438.2K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 391 | $777.51 | −$304.0K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 521 | $776.43 | −$404.5K |
| 2026-02-11 | Pitofsky Jason | SVP Controller | S Open-market sale | 20 | $775.95 | −$15.5K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 10.85 | — | — |
| 2026-04-29 | 8.90 | 9.47 | +6.38% |
| 2026-01-30 | 10.75 | 11.44 | +6.38% |
| 2025-10-28 | 9.64 | 11.83 | +22.66% |
| 2025-08-01 | 8.44 | 12.89 | +52.72% |
| 2025-04-29 | 7.06 | 7.27 | +3.00% |
| 2025-02-04 | 11.19 | 12.07 | +7.82% |
| 2024-10-31 | 11.70 | 12.46 | +6.54% |
| 2024-08-01 | 10.62 | 11.56 | +8.83% |
| 2024-05-02 | 10.10 | 9.55 | -5.41% |
| 2024-02-02 | 10.75 | 11.86 | +10.37% |
| 2023-11-02 | 10.78 | 11.59 | +7.56% |
| 2023-08-03 | 9.90 | 10.24 | +3.47% |
| 2023-05-04 | 9.56 | 10.09 | +5.55% |
| 2023-02-03 | 10.01 | 12.56 | +25.48% |
| 2022-11-03 | 9.48 | 11.14 | +17.56% |